Patents by Inventor Matthew B. Schabath

Matthew B. Schabath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOMICS-BASED TREATMENT DECISION SUPPORT FOR LUNG CANCER
    Publication number: 20230038185
    Abstract: Two major treatment strategies employed in fighting non-small cell lung cancer (NSCLC) are tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The choice of strategy is based on heterogeneous biomarkers expressed by the lung tumor tissue. A major challenge for molecular testing of these biomarkers is the insufficiency of biopsy specimens from patients with advanced NSCLC. Disclosed herein is a method for predicting a response to immune-checkpoint blockade immunotherapy.
    Type: Application
    Filed: December 7, 2020
    Publication date: February 9, 2023
    Inventors: Robert J. Gillies, Matthew B. Schabath, Wei MU
  • Methods for assessing cancer susceptibility to carcinogens in tobacco products
    Patent number: 8394592
    Abstract: The present invention demonstrates the differential sensitivity of PBLs from lung cancer patients and healthy controls to NNK-induced genetic damage. The data provide convincing evidence that the preferred CBMN assay is a robust test for detection of this sensitivity and yields results that are a good predictor of, for example, lung cancer risk. The simplicity, rapidity, and sensitivity of the CBMN test make it a valuable tool for screening and, for example, prioritizing potential cases for early detection of the disease.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: March 12, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Randa A. El-Zein, Matthew B. Schabath, Carol J. Etzel, Mirtha S. Lopez, Margaret R. Spitz
  • Methods for Assessing Cancer Susceptibility to Carcinogens in Tobacco Products
    Publication number: 20100173289
    Abstract: The present invention demonstrates the differential sensitivity of PBLs from lung cancer patients and healthy controls to NNK-induced genetic damage. The data provide convincing evidence that the preferred CBMN assay is a robust test for detection of this sensitivity and yields results that are a good predictor of, for example, lung cancer risk. The simplicity, rapidity, and sensitivity of the CBMN test make it a valuable tool for screening and, for example, prioritizing potential cases for early detection of the disease.
    Type: Application
    Filed: June 11, 2007
    Publication date: July 8, 2010
    Applicant: The Board of Regents, of the University of Texas System
    Inventors: Randa A. El-Zein, Matthew B. Schabath, Carol J. Etzel, Mirtha S. Lopez, Margaret R. Spitz